Compare OSCR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSCR | RDY |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.9B |
| IPO Year | 2021 | 2001 |
| Metric | OSCR | RDY |
|---|---|---|
| Price | $31.78 | $14.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $36.40 | $14.30 |
| AVG Volume (30 Days) | ★ 4.4M | 2.8M |
| Earning Date | 11-05-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $11,701,427,000.00 | N/A |
| Revenue This Year | $60.08 | $4.59 |
| Revenue Next Year | $10.95 | $12.06 |
| P/E Ratio | ★ $9.87 | $18.67 |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $10.69 | $11.36 |
| 52 Week High | $35.01 | $15.67 |
| Indicator | OSCR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 78.00 |
| Support Level | $28.16 | $12.92 |
| Resistance Level | $32.73 | $14.71 |
| Average True Range (ATR) | 1.43 | 0.22 |
| MACD | -0.23 | 0.10 |
| Stochastic Oscillator | 37.59 | 99.01 |
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.